Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01504932 · ClinicalTrials.gov registry record · NA
Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors
A NA study of Stage III Squamous Cell Carcinoma of the Oropharynx and Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT01504932: Completed NA study of Stage III Squamous Cell Carcinoma of the Oropharynx and Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01504932 is a NA study of Stage III Squamous Cell Carcinoma of the Oropharynx and Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 42 participants, below the 151-participant average among 4 other Stage III Squamous Cell Carcinoma of the Oropharynx trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01504932, a NA study of Stage III Squamous Cell Carcinoma of the Oropharynx and Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies freeze-dried black raspberries (BRB) in preventing oral cancer recurrence in high at-risk Appalachian patients previously treated with surgery for oral cancer. Chemoprevention is the use of drugs natural products to keep cancer from developing, progressing, or recurring. Giving freeze-dried black raspberries may prevent oral cancer from forming or returning in oral cancer survivors.
Primary Outcome
Two side tests and confidence intervals will be constructed using the exact binomial formulation.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Survey Administration
- OTHER pharmacological study
- DIETARY_SUPPLEMENT BRB Lozenge
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-02-23 |
| Est. Completion | 2015-04-22 |
| Phase | NA |
What the finished NCT01504932 record still lists
NCT01504932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 151-participant average among 4 other Stage III Squamous Cell Carcinoma of the Oropharynx trials with a reported enrollment target (72% lower).
The record links to 10 conditions, with Stage III Squamous Cell Carcinoma of the Oropharynx appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01504932 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01504932 about?
NCT01504932 is a clinical study titled "Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors". This pilot clinical trial studies freeze-dried black raspberries (BRB) in preventing oral cancer recurrence in high at-risk Appalachian patients previously treated with surgery for oral cancer. Chemoprevention is the use of drugs natural products to keep cancer from developing, progressing, or recur...
What is the current status of trial NCT01504932?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2007-02-23. Estimated completion is 2015-04-22.
What conditions does trial NCT01504932 study?
This clinical trial studies the following conditions: Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Verrucous Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx.
What interventions are being tested in trial NCT01504932?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Survey Administration (OTHER), pharmacological study (OTHER), BRB Lozenge (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01504932?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01504932 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Squamous Cell Carcinoma of the Oropharynx
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
COMPLETED · Phase 1
-
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
COMPLETED · Phase 1
-
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI